Novel molecules for the correction of factor Xa generation and phenotype in hemophilia

Thrombosis Research

Volumn 129, Issue SUPPL. 2, 2012, Pages

  Persson, Egon ^a  

^a NOVO NORDISK A S   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATED PROTHROMBIN COMPLEX; BAY 86 6150; BLOOD CLOTTING FACTOR 10A; BLOOD CLOTTING FACTOR 7A; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 9; BLOOD CLOTTING FACTOR 9A; NEUTRALIZING ANTIBODY; RECOMBINANT BLOOD CLOTTING FACTOR 7A; UNCLASSIFIED DRUG;

BLEEDING; BLOOD CLOTTING; HEMOPHILIA; HEMOPHILIA A; HEMOPHILIA B; HEMOSTASIS; HUMAN; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; REVIEW; TREATMENT OUTCOME;

EID: 84859790047     PISSN: 00493848     EISSN: 18792472     Source Type: Journal    
DOI: 10.1016/j.thromres.2012.02.033     Document Type: Article

References (38)

1. Davie EW, Fujikawa K, Kisiel W. The coagulation cascade: Initiation, maintenance, and regulation. Biochemistry 1991;30:10363-70.
2. MonroeDM, Hoffman M, Roberts HR. Platelets and thrombin generation. Arterioscler Thromb Vasc Biol 2002;22:1381-9.
3. Nordfang O, Valentin S, Beck TC, Hedner U. Inhibition of extrinsic pathway inhibitor shortens the coagulation time of normal plasma and of hemophilia plasma. Thromb Haemost 1991;66:464-7.
4. Erhardtsen E, Ezban M, Madsen MT, Diness V, Glazer S, Hedner U, et al. Blocking of tissue factor pathway inhibitor (TFPI) shortens the bleeding time in rabbits with antibody induced haemophilia A. Blood Coagul Fibrinolysis 1995;6:388-94.
5. Breinholt J, Svensson LA, Hilden I, Krogh BO, Olsen OH, Pass J, et al. The extensive epitope overlap of the humanized monoclonal antibody mAb 2021 with the FXa binding site on K2 explains its neutralizing effect on TFPI. J Thromb Haemost 2011;9(Suppl. 2):P-MO-111 abstract.
6. Sorensen BB, Hilden I, Petersen LC, Hermit MB, Petersen HH, Balling KW. A monoclonal antibody mAb 2021 blocking tissue factor pathway inhibitor (TFPI) enhances haemostasis under haemophilia A-like conditions. J Thromb Haemost 2011;9(Suppl. 2):P-MO-123 abstract.
7. Petersen LC, Hilden I, Bjoern S, Soerensen BB. Blocking of tissue factor pathway inhibitor (TFPI) with mAb 2021 promotes thrombin generation in FVIII-deficient plasma. J Thromb Haemost 2011;9(Suppl. 2):P-TU-137 abstract.
8. Lauritzen B,HermitMB, Balling KW, AgersoeH, Sorensen BB,Hilden I. Amonoclonal anti- TFPI antibody,mAb 2021, reduces bleeding in haemophilic rabbits after intravenous and subcutaneous administration. J Thromb Haemost 2011;9(Suppl. 2):P-MO-120 abstract.
9. Lauritzen B, Hilden I, Sorensen BB. A monoclonal anti-TFPI antibody, mAb 2021, reduces an ongoing bleeding in haemophilic rabbits with a similar effect as rFVIIa. J Thromb Haemost 2011;9(Suppl. 2):O-TU-113 abstract.
10. Waters EK, Genga RM, Schwartz MC, Nelson JA, Schaub RG, Olson KA, et al. Aptamer ARC19499 mediates a procoagulant hemostatic effect by inhibiting tissue factor pathway inhibitor. Blood 2011;117:5514-22.
11. Gorczyca M, Male C, Pabinger I, Reitter S, Knoebl P, McGinness KE, et al. Inhibition of tissue factor inhibitor by ARC19499 (BAX499) improves ex vivo clotting in hemophilia patients. J Thromb Haemost 2011;9(Suppl. 2):O-TU-028 abstract.
12. Shenbagapriya P, Chandran NS, Mercy D, Aby A, Vikram M, Alok S. Aptamer BAX499, a potent and specific inhibitor of TFPI, corrects hemostasis parameters of hemohilic blood. J Thromb Haemost 2011;9(Suppl. 2):O-TU-076 abstract.
13. Butenas S, Gissel M, Orfeo T, Mann KG. Tissue factor pathway inhibitor aptamer as a potential drug for hemophilia treatment. J Thromb Haemost 2011;9(Suppl. 2): O-MO-114 abstract.
14. Dockal M, Fries M, Brandstetter J, Ludwiczek M, Kontaxis G, Prohaska K, et al. Peptides binding to Kunitz domain 1 of tissue factor pathway inhibitor inhibit the interaction with factor Xa. J Thromb Haemost 2011;9(Suppl. 2):O-MO-057 abstract.
15. DockalM, Thomassen CLGD, Heinzmann ACA, Duckers C, Hartmann R, Scheiflinger F, et al. Inhibition of tissue factor pathway inhibitor (TFPI) by small peptides protects FXa and enhances FXa and thrombin formation in model systems and in plasma. J Thromb Haemost 2011;9(Suppl. 2):O-MO-112 abstract.
16. Dockal M, Hartmann R, Polakowski T, Osterkamp F, Kammlander W, Panholzer E, et al. Improvement of hemostasis in hemophilia by peptides inhibiting tissue factor pathway inhibitor. J Thromb Haemost 2011;9(Suppl. 2):P-TU-129 abstract.
17. Hoellriegl W, Dockal M, Schiviz A, Lawo JP, Verdino D, Leidenmuehler P, et al. Inhibition of TFPI efficiently improves hemostasis in hemophilic mice. J Thromb Haemost 2011;9(Suppl. 2):P-WE-126 abstract.
18. Liu T, Scallan CD, Broze GJ, Patarroyo-White S, Pierce GF, Johnson KW. Improved coagulation in bleeding disorders by non-anticoagulant sulfated polysaccharides (NASP). Thromb Haemost 2006;95:68-76.
19. Prasad S, Lillicrap D, Labelle A, Knappe S, Keller T, Burnett E, et al. Efficacy and safety of a new-class hemostatic drug candidate, AV513, in dogs with hemophilia A. Blood 2008;111:672-9.
20. Persson E, Kjalke M, Olsen OH. Rational design of coagulation factor VIIa variants with substantially increased intrinsic activity. Proc Natl Acad Sci U S A 2001;98: 13583-8. (Pubitemid 33115941)
21. Allen GA, Persson E, Campbell RA, Ezban M, Hedner U, Wolberg AS. A variant of recombinant factor VIIa with enhanced procoagulant and antifibrinolytic activities in an in vitro model of hemophilia. Arterioscler Thromb Vasc Biol 2007;27: 683-9.
22. Sørensen B, Persson E, Ingerslev J. Factor VIIa analogue (V158D/E296V/M298Q-FVIIa) normalises clot formation inwhole blood from patientswith severe haemophilia A. Br J Haematol 2007;137:158-65. (Pubitemid 46474712)
23. Holmberg H, Lauritzen B, Tranholm M, Ezban M. Faster onset of effect and greater efficacy of NN1731 compared with rFVIIa, aPCC and FVIII in tail bleeding in hemophilic mice. J Thromb Haemost 2009;7:1517-22.
24. De Paula EV, Kavakli K, Mahlangu J, Ayob Y, Lentz SR, Morfini M, et al. Recombinant factor VIIa analog (vatreptacog alfa [activated]) for treatment of joint bleeds in hemophilia patients with inhibitors: a randomized controlled trial. J Thromb Haemost 2012;10:81-9.
25. Shah AM, Kisiel W, Foster DC, Nelsestuen GL. Manipulation of the membrane binding site of vitamin K-dependent proteins: Enhanced biological function of human factor VII. Proc Natl Acad Sci U S A 1998;95:4229-34. (Pubitemid 28207894)
26. Harvey SB, StoneMD,MartinezMB,NelsestuenGL.Mutagenesis of the γ-carboxyglutamic acid domain of human factor VII to generate maximum enhancement of the membrane contact site. J Biol Chem 2003;278:8363-9. (Pubitemid 36800585)
27. Sim DS, Koellnberger M, Gu JM, Bornaes C, Kragh M, Clausen SK, et al. BAY 86-6150, a novel recombinant factor VIIa variant, has a significantly higher therapeutic index than eptacog alfa (activated) in rabbit bleeding and thrombosis models. J Thromb Haemost 2011;9(Suppl. 2):O-TU-114 abstract.
28. Salas J, Ashworth T, Kistanova E, Patel R, Sakorafas P, Pape B, et al. Targeting factor VIIa to platelet receptors results in enhanced activity. J Thromb Haemost 2011;9(Suppl. 2):O-TU-078 abstract.
29. Huang X, Ding WQ, Vaught JL, Wolf RF, Morrissey JH, Harrison RG, et al. A soluble tissue factor-annexin V chimeric protein has both procoagulant and anticoagulant properties. Blood 2006;107:980-6. (Pubitemid 43156295)
30. Hartmann R, Dockal M, Kammlander W, Panholzer E, Nicolaes GA, Fiedler C, et al. Factor IX mutants with enhanced catalytic activity. J Thromb Haemost 2009;7: 1656-62.
31. Lin CN, Kao CY, Miao CH, Hamaguchi N, Wu HL, Shi GY, et al. Generation of a novel factor IX with augmented clotting activities in vitro and in vivo. J Thromb Haemost 2010;8:1773-83.
32. Kao CY, Lin CN, Yu IS, Tao MH, Wu HL, Shi GY, et al. FIX-Triple, a gain-of-function factor IX variant, improves haemostasis in mouse models without increased risk of thrombosis. Thromb Haemost 2010;104:355-65.
33. Milanov P, Ivanciu L, Abriss D, Quade-Lyssy P, Miesbach W, Alesci S, et al. Engineered factor IX variants bypass FVIII and correct hemophilia A phenotype in mice. Blood 2012;119:602-11.
34. Scheiflinger F, Dockal M, Rosing J, Kerschbaumer RJ. Enhancement of the enzymatic activity of activated coagulation factor IX by anti-factor IX antibodies. J Thromb Haemost 2008;6:315-22.
35. Thorn K, Toby G, Hsiao KC, Seidel S, Donnelly R, Rakhe S, et al. Synthetic peptides discovered by phage display enhance the activity of hFIXa in functional coagulation assays. J Thromb Haemost 2011;9(Suppl. 2):O-TU-075 abstract.
36. Louvain-Quintard VB, Bianchini EP, Calmel-Tareau C, Tagzirt M, LeBonniec BF. Thrombin-activable factor X re-establishes an intrinsic amplification in tenasedeficient plasmas. J Biol Chem 2005;280:41352-9. (Pubitemid 41832192)
37. Bunce MW, Toso R, Camire RM. Zymogen-like factor Xa variants restore thrombin generation and effectively bypass the intrinsic pathway in vitro. Blood 2011;117: 290-8.
38. Ivanciu L, Toso R, Margaritis P, Pavani G, Kim H, Schlachtermann A, et al. A zymogen-like factor Xa variant corrects the coagulation defect in hemophilia. Nat Biotechnol 2011;29:1028-33.